Hematopoietic Stem Cell Transplantation for the Management of Follicular Lymphoma

Overview

Journal Stem Cells Cloning

Publisher Dove Medical Press

Specialty Biotechnology

Date 2013 Nov 8

PMID 24198512

Authors

Chitra Hosing

Affiliations

Soon will be listed here.

Abstract

Although much has been published on the application of autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma (FL), no uniform consensus exists among physicians on when to use this strategy. Three large randomized trials failed to show a survival benefit using autologous transplantation for FL patients in first complete remission. Similarly, many Phase II or registry-based studies have also failed to show a survival benefit with autologous transplantation in relapsed or refractory FL patients, although the progression-free survival seems to be prolonged in transplant recipients. Allogeneic stem cell transplantation can cure a subset of patients with FL, but high nonrelapse mortality and morbidity remain a concern. No consensus exists on what conditioning regimen should be used, or how the newer monoclonal antibodies should be incorporated into the transplant paradigm. Here we present a review of the role of autologous and allogeneic hematopoietic stem cell transplantation in patients with FL.

References

Arcaini L, Montanari F, Alessandrino E, Tucci A, Brusamolino E, Gargantini L . Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol. 2008; 19(7):1331-1335. DOI: 10.1093/annonc/mdn044. View

Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T . Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol. 2008; 26(19):3166-75. DOI: 10.1200/JCO.2007.14.4204. View

Rohatiner A, Nadler L, Davies A, Apostolidis J, Neuberg D, Matthews J . Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007; 25(18):2554-9. DOI: 10.1200/JCO.2006.09.8327. View

Surbone A, Armitage J, Gale R . Autotransplantation in lymphoma: better therapy or healthier patients?. Ann Intern Med. 1991; 114(12):1059-60. DOI: 10.7326/0003-4819-114-12-1059. View

Robinson S, Goldstone A, Mackinnon S, Carella A, Russell N, de Elvira C . Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002; 100(13):4310-6. DOI: 10.1182/blood-2001-11-0107. View

Rohatiner A, FREEDMAN A, NADLER L, Lim J, Lister T . Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma. Ann Oncol. 1994; 5 Suppl 2:143-6. DOI: 10.1093/annonc/5.suppl_2.s143. View

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H . Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008; 26(32):5156-64. DOI: 10.1200/JCO.2008.17.2015. View

Kuruvilla J, Pond G, Tsang R, Gupta V, Lipton J, Messner H . Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma. Biol Blood Marrow Transplant. 2008; 14(7):775-82. DOI: 10.1016/j.bbmt.2008.04.007. View

Stein R, Greer J, Goodman S, Kallianpur A, Ahmed M, Wolff S . High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant. 1999; 23(3):227-33. DOI: 10.1038/sj.bmt.1701556. View

10.

Weiden P, Flournoy N, Sanders J, Sullivan K, Thomas E . Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc. 1981; 13(1 Pt 1):248-51. View

11.

Horowitz M, Gale R, Sondel P, Goldman J, Kersey J, Kolb H . Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990; 75(3):555-62. View

12.

Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A . Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall.... Blood. 2008; 111(8):4004-13. DOI: 10.1182/blood-2007-10-116749. View

13.

Freedman A, Gribben J, Neuberg D, Mauch P, Soiffer R, Anderson K . High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996; 88(7):2780-6. View

14.

Morris E, Mackinnon S . Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Transfus Apher Sci. 2005; 32(1):73-83. DOI: 10.1016/j.transci.2004.10.008. View

15.

Verdonck L, Dekker A, Lokhorst H, Petersen E, Nieuwenhuis H . Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood. 1997; 90(10):4201-5. View

16.

Hosing C, Saliba R, McLaughlin P, Andersson B, Rodriguez M, Fayad L . Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol. 2003; 14(5):737-44. DOI: 10.1093/annonc/mdg200. View

17.

Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N . Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol. 2008; 26(21):3614-20. DOI: 10.1200/JCO.2007.15.5358. View

18.

Montoto S, Canals C, Rohatiner A, Taghipour G, Sureda A, Schmitz N . Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007; 21(11):2324-31. DOI: 10.1038/sj.leu.2404850. View

19.

Czuczman M, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A . Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004; 22(23):4711-6. DOI: 10.1200/JCO.2004.04.020. View

20.

Apostolidis J, Gupta R, Grenzelias D, Johnson P, Pappa V, Summers K . High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 2000; 18(3):527-36. DOI: 10.1200/JCO.2000.18.3.527. View